XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.20.2

Stock-Based Compensation | 9 Months Ended
--- | ---
Sep. 30, 2020
Share-based Payment Arrangement [Abstract] |
Stock-Based Compensation | STOCK-BASED COMPENSATION Our 2014 Long Term Stock Incentive Plan provides for the issuance of stock-based incentives in various forms to our employees and non-employee Directors. At September 30, 2020, outstanding stock-based incentives were in the form of long-term stock awards, stock options, restricted stock units, performance restricted stock units, and phantom stock awards. Pre-tax compensation expense included in income from continuing operations for these stock-based incentives was as follows, in millions:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Long-term stock awards | $ | 4 |  |  | $ | 6 |  |  | $ | 11 |  |  | $ | 16 |
Stock options | 1 |  |  | 1 |  |  | 6 |  |  | 3 |
Restricted stock units | 1 |  |  | — |  |  | 12 |  |  | — |
Performance restricted stock units | 2 |  |  | — |  |  | 3 |  |  | 2 |
Phantom stock awards and stock appreciation rights | 1 |  |  | 1 |  |  | 3 |  |  | 3 |
Total | $ | 9 |  |  | $ | 8 |  |  | $ | 35 |  |  | $ | 24 |
Long-Term Stock Awards. Prior to the amendment of our 2014 Long Term Stock Incentive Plan in December 2019, we granted long-term stock awards to our key employees and non-employee Directors. These grants did not cause net share dilution due to our practice of repurchasing and retiring an equal number of shares in the open market. We did not grant shares of long-term stock awards in the nine-month period ended September 30, 2020. Our long-term stock award activity was as follows, shares in millions:
| Nine Months Ended September 30,
| 2020 |  | 2019
Unvested stock award shares at January 1 | 2 |  |  | 2 |
Weighted average grant date fair value | $ | 34 |  |  | $ | 30 |
Stock award shares granted | — |  |  | 1 |
Weighted average grant date fair value | $ | — |  |  | $ | 36 |
Stock award shares vested | 1 |  |  | 1 |
Weighted average grant date fair value | $ | 32 |  |  | $ | 25 |
Stock award shares forfeited | — |  |  | — |
Weighted average grant date fair value | $ | 35 |  |  | $ | 32 |
Unvested stock award shares at September 30 | 1 |  |  | 2 |
Weighted average grant date fair value | $ | 36 |  |  | $ | 34 |
At September 30, 2020 and 2019, there was $25 million and $49 million, respectively, of total unrecognized compensation expense related to unvested stock awards; such awards had a weighted average remaining vesting period of two years and three years at September 30, 2020 and 2019, respectively. The total market value (at the vesting date) of stock award shares which vested was $31 million during both the nine-month periods ended September 30, 2020 and 2019. J. STOCK-BASED COMPENSATION (Continued) Stock Options. Stock options are granted to certain key employees. The exercise price equals the market price of our common stock at the grant date. Beginning in 2020, stock options become exercisable (vest ratably) over three years beginning on the first anniversary from the grant date. Stock options granted prior to 2020 become exercisable (vest ratably) over five years. We granted 420,840 stock options in the nine-month period ended September 30, 2020 with a grant date weighted average exercise price of approximately $48 per share. In the nine-month period ended September 30, 2020, 16,240 stock options were forfeited (including options that expired unexercised). Our stock option activity was as follows, shares in millions:
|  | Nine Months Ended September 30,
|  | 2020 |  |  | 2019
Option shares outstanding, January 1 |  | 3 |  |  |  | 4 |
Weighted average exercise price | $ | 27 |  |  | $ | 21 |
Option shares granted |  | 1 |  |  |  | 1 |
Weighted average exercise price | $ | 48 |  |  | $ | 36 |
Option shares exercised |  | 1 |  |  |  | 2 |
Aggregate intrinsic value on date of exercise (A) | $ | 29 million |  | $ | 29 million
Weighted average exercise price | $ | 17 |  |  | $ | 12 |
Option shares forfeited |  | — |  |  |  | — |
Weighted average exercise price | $ | 42 |  |  | $ | 34 |
Option shares outstanding, September 30 |  | 3 |  |  |  | 3 |
Weighted average exercise price | $ | 34 |  |  | $ | 26 |
Weighted average remaining option term (in years) |  | 7 |  |  | 6
Option shares vested and expected to vest, September 30 |  | 2 |  |  |  | 3 |
Weighted average exercise price | $ | 33 |  |  | $ | 26 |
Aggregate intrinsic value (A) | $ | 54 million |  | $ | 48 million
Weighted average remaining option term (in years) |  | 7 |  |  | 6
Option shares exercisable (vested), September 30 |  | 1 |  |  |  | 2 |
Weighted average exercise price | $ | 28 |  |  | $ | 21 |
Aggregate intrinsic value (A) | $ | 35 million |  | $ | 39 million
Weighted average remaining option term (in years) |  | 5 |  |  | 4
(A) Aggregate intrinsic value is calculated using our stock price at each respective date, less the exercise price (grant date price), multiplied by the number of shares. At September 30, 2020 and 2019, there was $7 million and $9 million, respectively, of unrecognized compensation expense (using the Black-Scholes option pricing model at the grant date) related to unvested stock options; such options had a weighted average remaining vesting period of three years at both September 30, 2020 and 2019. J. STOCK-BASED COMPENSATION (Concluded) The weighted average grant date fair value of option shares granted and the assumptions used to estimate those values using a Black-Scholes option pricing model were as follows:
| Nine Months Ended September 30,
| 2020 |  | 2019
Weighted average grant date fair value | $ | 10.67 |  |  | $ | 8.81 |
Risk-free interest rate | 1.53 | % |  | 2.57 | %
Dividend yield | 1.14 | % |  | 1.35 | %
Volatility factor | 24.00 | % |  | 25.00 | %
Expected option life | 6 years |  | 6 years
Restricted Stock Units. Restricted stock units are granted to our key employees and non-employee Directors. These grants did not cause net share dilution due to our practice of repurchasing and retiring an equal number of shares in the open market. The grant date fair value is based on the fair value of our common stock. These units will vest and be settled in shares ratably over three years. We granted 437,170 restricted stock units in the nine-month period ended September 30, 2020 with a weighted average grant date fair value of $47 per share. In the nine-month period ended September 30, 2020, 7,930 restricted stock units were forfeited. At September 30, 2020, there was $8 million of unrecognized compensation expense related to unvested restricted stock units; such units had a weighted average remaining vesting period of two years. Performance Restricted Stock Units. Under our Long Term Incentive Program, we grant performance restricted stock units to certain senior executives. These performance restricted stock units will vest and share awards will be issued at no cost to the employees, subject to our achievement of specified performance metrics established by our Compensation Committee over a three-year performance period and the recipient's continued employment through the share award date. During the nine-month period ended September 30, 2020, we granted 133,390 performance restricted stock units with a grant date fair value of approximately $34 per share and 151,724 shares were issued. No performance restricted stock units were forfeited during the nine-month period ended September 30, 2020. During the nine-month period ended September 30, 2019, we granted 126,680 performance restricted stock units with a grant date fair value of approximately $39 per share and 15,600 performance restricted stock units were forfeited.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration